The French drug manufacturer Sanofi wants to have a real impact on changes in the availability of therapy in low-income countries. And the word "impact" can be clearly emphasized here, because the distribution of drugs in a non-profit mode will be handled by a new brand: Impact.
Among the available therapies, there will be 30 Sanofi products, including those intended for patients with cancer, hypertension, malaria, and tuberculosis. There will also be insulin. In ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
